Float Short %

11.82

Margin Of Safety %

Put/Call OI Ratio

0.2

EPS Next Q Diff

-0.45

EPS Last/This Y

-0.36

EPS This/Next Y

-0.14

Price

51.1

Target Price

74.39

Analyst Recom

1.43

Performance Q

54.01

Relative Volume

1.03

Beta

0.61

Ticker: CYTK

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-08-15	CYTK	38.66	0.18	0.19	85813
2025-08-18	CYTK	38.97	0.18	0.00	71702
2025-08-19	CYTK	37.85	0.17	0.11	76218
2025-08-20	CYTK	37.32	0.17	0.55	77105
2025-08-21	CYTK	38.04	0.17	0.17	77318
2025-08-22	CYTK	38.33	0.17	0.24	77333
2025-08-25	CYTK	37.01	0.17	0.04	77418
2025-08-26	CYTK	38.17	0.17	0.23	77989
2025-08-27	CYTK	37.84	0.17	0.00	78351
2025-08-28	CYTK	37.33	0.16	0.10	82532
2025-08-29	CYTK	35.32	0.16	0.17	83754
2025-09-02	CYTK	49.59	0.16	0.13	85274
2025-09-03	CYTK	50.01	0.18	0.45	89457
2025-09-04	CYTK	49.76	0.19	0.27	88907
2025-09-05	CYTK	53.05	0.19	0.10	90522
2025-09-08	CYTK	52.08	0.20	0.55	90653
2025-09-09	CYTK	51.47	0.20	0.74	91166
2025-09-10	CYTK	52.02	0.20	0.17	91648
2025-09-11	CYTK	53.19	0.20	0.23	91892
2025-09-12	CYTK	51.25	0.20	0.24	92171
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-08-15	CYTK	38.66	-14.8	-111.4	-5.57
2025-08-18	CYTK	38.95	-14.8	-116.9	-5.57
2025-08-19	CYTK	37.84	-14.8	-94.5	-5.57
2025-08-20	CYTK	37.31	-14.8	-103.6	-5.57
2025-08-21	CYTK	38.05	-14.8	-124.7	-5.57
2025-08-22	CYTK	38.36	-14.8	-117.5	-5.57
2025-08-25	CYTK	37.01	-14.8	-90.6	-5.57
2025-08-26	CYTK	38.19	-14.8	-132.4	-5.57
2025-08-27	CYTK	37.81	-14.8	-106.1	-5.57
2025-08-28	CYTK	37.34	-14.8	-104.2	-5.57
2025-08-29	CYTK	35.31	-14.8	-78.0	-5.57
2025-09-02	CYTK	49.60	-14.6	-365.4	-5.57
2025-09-03	CYTK	50.01	-14.6	-109.2	-5.57
2025-09-04	CYTK	49.76	-14.6	-101.5	-5.57
2025-09-05	CYTK	53.01	-15.6	-146.0	-5.61
2025-09-08	CYTK	52.09	-15.5	-94.8	-5.62
2025-09-09	CYTK	51.56	-15.5	-99.1	-5.62
2025-09-10	CYTK	52.01	-15.5	-111.6	-5.62
2025-09-11	CYTK	53.32	-15.5	-121.2	-5.62
2025-09-12	CYTK	51.10	-15.5	-79.7	-5.62
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-08-15	CYTK	-9.69	7.96	13.26
2025-08-18	CYTK	-9.85	8.27	13.27
2025-08-19	CYTK	-9.77	8.27	13.27
2025-08-20	CYTK	-9.77	8.27	13.27
2025-08-21	CYTK	-9.77	8.27	13.27
2025-08-22	CYTK	-9.77	8.27	13.27
2025-08-25	CYTK	-9.77	2.06	13.27
2025-08-26	CYTK	-9.77	2.06	13.27
2025-08-27	CYTK	-9.77	2.06	13.10
2025-08-28	CYTK	-9.77	2.06	13.10
2025-08-29	CYTK	-9.77	2.06	13.10
2025-09-02	CYTK	-10.19	2.25	13.10
2025-09-03	CYTK	-10.19	2.25	13.10
2025-09-04	CYTK	-10.19	2.25	13.10
2025-09-05	CYTK	-10.11	2.25	13.10
2025-09-08	CYTK	-8.06	2.25	13.10
2025-09-09	CYTK	-8.09	2.25	13.10
2025-09-10	CYTK	-8.15	2.25	13.10
2025-09-11	CYTK	-8.15	2.25	11.82
2025-09-12	CYTK	-8.15	2.25	11.82
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.12

Avg. EPS Est. Current Quarter

-1.57

Avg. EPS Est. Next Quarter

-1.57

Insider Transactions

-8.15

Institutional Transactions

2.25

Beta

0.61

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

53.7

Max Drawdown 5-Year %

-72.4

Target Price

74.39

P/E

Forward P/E

PEG

P/S

71.36

P/B

P/Free Cash Flow

EPS

-5.12

Average EPS Est. Cur. Y

-5.62

EPS Next Y. (Est.)

-5.75

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-707.17

Relative Volume

1.03

Return on Equity vs Sector %

139.6

Return on Equity vs Industry %

152.7

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.08

EBIT Estimation

-79.7

Cytokinetics, Incorporated

Sector: Healthcare

Industry: Biotechnology

Employees: 498

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

stock quote shares CYTK – Cytokinetics, Incorporated Stock Price stock today

news today CYTK – Cytokinetics, Incorporated stock forecast ,stock prediction 2023 2024 2025

marketwatch CYTK – Cytokinetics, Incorporated yahoo finance google finance

stock history CYTK – Cytokinetics, Incorporated invest stock market

stock prices CYTK premarket after hours

ticker CYTK fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: CYTK

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y